The global Mice Model Market, valued at US$1.53 billion in 2024, is anticipated to reach US$2.74 billion by 2030, representing a robust CAGR of 10.0% during 2025-2030. This growth trajectory is fueled by factors such as the increasing adoption of mice models in preclinical studies, rising demand for personalized medicine in oncology, and advancements in genetic engineering techniques like CRISPR. The CRISPR technology, in particular, is driving significant market expansion due to its precise genome editing applications, enabling gene knockouts and transgenesis with efficiency.
In the market segmentation by model type, inbred mice emerged as the largest segment in 2024, offering genetically identical strains that support reproducible results in various research fields. These models find applications in pharmacology, oncology, behavioral studies, and therapeutic validation, underlining their versatility and importance in biomedical research. The technology segment highlights CRISPR/Cas9 as a dominant player in 2024, given its effectiveness in targeted DNA cleavage and multiplexed gene editing capabilities, streamlining genetic screening processes and enhancing research efficiency.
Geographically, North America led the mice model market in 2024, driven by its robust infrastructure for biomedical research, stringent regulatory frameworks, and the presence of key market players. Companies like Charles River Laboratories, The Jackson Laboratory, and Inotiv play pivotal roles in advancing research and development in this market through their comprehensive services and innovative approaches. These players are instrumental in developing specialized strains, expanding global production networks, and fostering strategic collaborations to drive market growth and technological advancements.
Key market players such as Charles River Laboratories, The Jackson Laboratory, and Inotiv stand out for their contributions to the mice model market through a diverse portfolio of research strains, advanced genetic engineering technologies, and strategic acquisitions. These companies are committed to innovation, regulatory compliance, and excellence in service delivery, reflecting their pivotal roles in shaping the future of biomedical research and preclinical studies. The emphasis on R&D, global distribution networks, and collaborative partnerships underscores the industry’s focus on driving advancements in personalized medicine and therapeutic development.
The mice model market presents significant opportunities for growth and innovation, propelled by technological advancements, increasing demand for disease-specific models, and the pursuit of personalized medicine solutions. As the market continues to evolve, key players are expected to leverage their expertise, infrastructure, and partnerships to drive transformative changes in preclinical research, drug development, and therapeutic validation. The convergence of genetic engineering technologies, regulatory frameworks, and market dynamics positions the mice model market for substantial growth and impact in the coming years.
Key Takeaways:
1. The mice model market is poised to reach US$2.74 billion by 2030, driven by factors such as genetic versatility, personalized medicine demand, and CRISPR technology.
2. Inbred mice and CRISPR/Cas9 technology segments are key growth drivers, offering reproducibility in research and precise genome editing capabilities.
3. North America leads the market, supported by established research infrastructure and key players like Charles River Laboratories, The Jackson Laboratory, and Inotiv driving innovation.
4. Market players’ strategic initiatives in R&D, acquisitions, and collaborations are shaping the future of biomedical research and preclinical studies, emphasizing innovation and regulatory alignment.
Tags: personalized medicine, clinical trials, gene knockouts, genome editing, regulatory, toxicology, biotech
Read more on finanznachrichten.de